JP2023523211A5 - - Google Patents
Info
- Publication number
- JP2023523211A5 JP2023523211A5 JP2022563882A JP2022563882A JP2023523211A5 JP 2023523211 A5 JP2023523211 A5 JP 2023523211A5 JP 2022563882 A JP2022563882 A JP 2022563882A JP 2022563882 A JP2022563882 A JP 2022563882A JP 2023523211 A5 JP2023523211 A5 JP 2023523211A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20315217.8 | 2020-04-24 | ||
| EP20315217 | 2020-04-24 | ||
| EP20305407 | 2020-04-27 | ||
| EP20305407.7 | 2020-04-27 | ||
| PCT/EP2021/060647 WO2021214282A1 (en) | 2020-04-24 | 2021-04-23 | Methods for preventing induction of immune responses to the transduced cells expressing a transgene product after ocular gene therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523211A JP2023523211A (ja) | 2023-06-02 |
| JPWO2021214282A5 JPWO2021214282A5 (https=) | 2024-02-08 |
| JP2023523211A5 true JP2023523211A5 (https=) | 2024-02-08 |
Family
ID=75625591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563882A Pending JP2023523211A (ja) | 2020-04-24 | 2021-04-23 | 眼科遺伝子治療後の、導入遺伝子産物を発現する形質転換細胞に対する免疫応答の誘導を防止するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230190956A1 (https=) |
| EP (1) | EP4138929A1 (https=) |
| JP (1) | JP2023523211A (https=) |
| CA (1) | CA3179895A1 (https=) |
| WO (1) | WO2021214282A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026005189A1 (ko) * | 2024-06-27 | 2026-01-02 | 이엔셀 주식회사 | 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639872A (en) | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
| WO1997020925A1 (en) | 1995-12-08 | 1997-06-12 | Hybridon, Inc. | Modified vegf antisense oligonucleotides for treatment of skin disorders |
| US20030144221A1 (en) | 2001-07-17 | 2003-07-31 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL2-associated X protein expression |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| AU2005222902B2 (en) | 2004-03-12 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
| EP1919497B1 (en) | 2005-07-22 | 2020-02-12 | The Board of Trustees of the Leland Stanford Junior University | Light-activated cation channel and uses thereof |
| EP2019588A4 (en) | 2006-05-04 | 2010-11-24 | Univ Wayne State | RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN |
| US7872118B2 (en) | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
| US20100081707A1 (en) | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| HRP20171334T1 (hr) | 2011-04-22 | 2017-11-17 | The Regents Of The University Of California | Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe |
| JP6348064B2 (ja) * | 2011-11-22 | 2018-06-27 | ザ チルドレンズ ホスピタル オブ フィラデルフィア | 効率の高いトランスジーン送達のためのウイルスベクター |
| ES2908467T3 (es) * | 2016-04-29 | 2022-04-29 | Adverum Biotechnologies Inc | Evasión de anticuerpos neutralizantes por un virus adenoasociado recombinante |
-
2021
- 2021-04-23 CA CA3179895A patent/CA3179895A1/en active Pending
- 2021-04-23 WO PCT/EP2021/060647 patent/WO2021214282A1/en not_active Ceased
- 2021-04-23 JP JP2022563882A patent/JP2023523211A/ja active Pending
- 2021-04-23 EP EP21720493.2A patent/EP4138929A1/en not_active Withdrawn
- 2021-04-23 US US17/996,987 patent/US20230190956A1/en active Pending